Abstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating acetylhydrolase (PAF-AH), has been recently proposed as an inflammatory biomarker and independent risk predictor for cardiovascular disease [1]. Moreover, several studies have demonstrated the clinical significance of several polymorphisms of the Lp-PLA2 gene for the cardiovascular system [2]. The single nucleotide polymorphism (SNP) Alanine379Valine (Ala379Val) at position 379 at chromosome 6 of the gene encoding Lp-PLA2 has been shown to have an ambiguous role in the onset and development of cardiovascular diseases [3–6].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
